WvT assists OpGen

OpGen Inc. agreed to merge with healthcare equipment company Curetis N.V. in a stock-for-stock transaction.

Under the agreement, OpGen will issue 2,662,564 new common shares to acquire all shares of Curetis. The combined company will be based in Gaithersburg, Md., and will be listed on the Nasdaq as a molecular diagnostics and bioinformatics franchise.

Curetis shareholders will own about 72.5% of OpGen, while OpGen shareholders will own about 27.5% after the issue of new shares.

OpGen expects to complete the transaction by early 2020, subject to closing conditions including approval by shareholders of both companies, consent from debt financers and listing of new shares on the Nasdaq.

Weidema van Tol assisted Ballard Spahr LLP as lead counsel to OpGen.